Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Operating Expenses (2016 - 2026)

Ani Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $212.3 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 8.9% to $212.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $772.3 million, a 25.82% increase, with the full-year FY2025 number at $772.3 million, up 25.82% from a year prior.
  • Operating Expenses hit $212.3 million in Q4 2025 for Ani Pharmaceuticals, up from $191.6 million in the prior quarter.
  • Over the last five years, Operating Expenses for ANIP hit a ceiling of $212.3 million in Q4 2025 and a floor of $51.5 million in Q1 2021.
  • Historically, Operating Expenses has averaged $121.7 million across 5 years, with a median of $109.0 million in 2023.
  • Biggest five-year swings in Operating Expenses: decreased 10.66% in 2021 and later skyrocketed 62.55% in 2022.
  • Tracing ANIP's Operating Expenses over 5 years: stood at $84.7 million in 2021, then increased by 9.17% to $92.4 million in 2022, then skyrocketed by 35.19% to $124.9 million in 2023, then skyrocketed by 56.05% to $195.0 million in 2024, then grew by 8.9% to $212.3 million in 2025.
  • Business Quant data shows Operating Expenses for ANIP at $212.3 million in Q4 2025, $191.6 million in Q3 2025, and $197.5 million in Q2 2025.